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cerns about safety and impact on patient outcomes. 
Attitudes about the proliferation of messages they per-
ceive as “false-positives” could explain the inconsistency
among pharmacist responses to drug interaction messages
(DIMs). Our objective is to report a pilot study examin-
ing pharmacist utilization and perceptions of DIMs.
METHODS: A semi-structured telephone interview 
protocol was developed using Likert scales assessing
pharmacists’ utilization and attitudes regarding DIMs.
Utilization measures included perception of false positive
DIMs and desensitization to DIMs. Attitude assessments
included conﬁdence, usefulness, and satisfaction with 
the drug interaction programs, and inﬂuence of liability
concerns. A convenience sample of 44 West Virginia 
pharmacists responded during March 2002. ANOVA was
used to analyze relationships among variables in this
descriptive study. RESULTS: Among respondents, 36.4%
perceived that 21–30% of DIMs were insigniﬁcant;
13.5% perceived that >50% of DIMs were insigniﬁcant.
Using a 5-point scale (1 = not at all, 5 = very much), phar-
macists reported desensitization to DIMs (median = 4.0).
Pharmacists perceiving DIMS as more insigniﬁcant also
reported greater desensitization to DIMs (F = 3.04, p <
.05). Pharmacists found the programs useful (median =
4.0), were somewhat conﬁdent (median = 3.5) or satisﬁed
with the programs (median = 3.0). Those who found the
program more useful (F = 6.38, p < .05), or were more
conﬁdent (F = 3.09, p < .05) or satisﬁed with the program
(F = 6.95, p < .05), were signiﬁcantly less desensitized to
DIMs. Also, the more desensitized to DIMs, the more 
the pharmacist was inﬂuenced by liability concerns in
deciding to report a DIM to the patient and/or physician
(F = 4.54, p < .01). CONCLUSIONS: These pilot results
suggest further research is warranted. Pharmacist utiliza-
tion of drug interaction programs is inconsistent; this may
be inﬂuenced by attitudes towards DIMs. Information
regarding attitudinal barriers can provide content for
pharmacist training or for vendor development of drug
interaction programs.
PHP22
REVIEWS OF UTAH MEDICAID HIGH UTILIZERS
TO CONTROL DRUG COSTS
Oderda GM1, Gunning K1, LaFleur J1, Stockdale W1,Tyler L1,
Parke D2, Orlando P1, Brixner D1
1University of Utah, Salt Lake City, UT, USA; 2Utah Medicaid,
Salt Lake City, UT, USA
OBJECTIVES: Utah Medicaid began a process to limit
patients to 7 paid non-exempt prescriptions per month
(maximum 30 day supply) in early 2002. Exempt 
prescriptions included prescriptions for antibiotics and
many chronic drugs, and more than one prescription for
the same NDC in the same month. One-third of pre-
scriptions are exempt. Prior to mandating the 7 prescrip-
tion limit Utah Medicaid contracted to develop a process
to improve drug use and reduce costs. The project objec-
tive is to describe and evaluate that process. METHODS:
Available data include eligibility ﬁles, pharmacy claims,
and medical claims, including ICD9 coding. Reviews
began in May 2002 and focus on the highest utilizers.
Two hundred patients are reviewed each month; 50
nursing home patients and 150 non-nursing home
patients. There were 249,447 Medicaid eligibles and
147,186 utilizers in FY2002. If drug related issues are
identiﬁed, letters are sent to prescribers with recommen-
dations along with a list of all prescription claims 
(including cost). RESULTS: Patients with >7 non-exempt
prescriptions have been reduced from 5593 in May 2002
to 2326 in September 2002. The ﬁrst review cohort (May
reviews) showed a reduction from 16.4 to 10.7 in mean
non-exempt prescriptions. Drug costs for the May cohort
in October were 46% lower than in May. The June and
July cohorts were reduced by 32% and 25% respectively;
June vs October, and July vs October while drug costs 
for non-reviewed patients increased at a 16% annual 
rate. Actual drug costs for the May cohort from May to
October were $1,042,643. This compares with an
expected cost of $1,592,564 (May costs increased by 
an annual 16%). Annualized cost savings for the May, 
June, and July cohorts are approximately $2.3M.
Program costs are approximately $300,000 per year.
CONCLUSION: Focused reviews of Medicaid high uti-
lizers, and communication with prescribers, can reduce
drug costs.
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OBJECTIVES: The objective of this study was to assess
whether prescribing incentive schemes offered to general
practitioners in England give appropriate incentives 
for cost-effective prescribing. METHODS: Prescribing
advisers from primary care trusts (PCTs) in England were
surveyed and asked to provide a copy of their prescrib-
ing incentive scheme, if available. The schemes were then
analysed in order to assess the types of incentives offered,
the targets (budgetary and non-budgetary) set and the
therapeutic areas covered. RESULTS: Responses were
obtained from 161 (50.4%) of the 319 PCTs existing 
in England in 2002. Of those responding, 109 supplied
copies of their prescribing incentive scheme, others stated
that their scheme was not ﬁnalized (N = 34), or offered
other reasons why it could not be supplied, such as 
conﬁdentiality concerns, or that no scheme was under
development. Of the schemes analysed, 26% offered the
maximum annual incentive of £45,000 per practice.
However, many offered incentives much lower than this
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amount. The achievement of budgetary targets was a
qualifying (i.e., mandatory) criterion for incentive 
payments in 59% of PCTs, but considerable discretion
was available. The therapeutic targets generally made
sense and included the promotion of generics and the
encouragement of appropriate prescribing of drugs that
are widely used (e.g., antibacterials). The schemes also
embodied different ways of assessing whether targets
were achieved, some using an “all or nothing” assess-
ment, others using a points system relating to the extent
to which various targets were achieved. CONCLU-
SIONS: Prescribing incentive schemes currently used by
PCTs in England offer modest ﬁnancial incentives to GPs.
Although the selection of prescribing targets generally
makes sense, the qualifying criteria and methods of
assessing target achievement are quite variable and non-
speciﬁc. Whilst not providing strong incentives to GPs,
they may make a contribution by signaling to prescribers
which elements of prescribing are important.
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OBJECTIVES: Generic competition has intensiﬁed in the
U.S. prescription drug industry. We seek to understand
the process of generic competition by developing a model
for the determinants of generic entry, prices, and gener-
ics’ market share. METHODS: We develop a simultane-
ous equation estimation framework to examine the
interaction among generic entry, prices, and market
shares. The model is estimated on a panel data sample
containing 40 brand name drugs that faced ﬁrst generic
competition during the period July 1992 through January
1998. The data period for each drug spans 36 months
before and 36 months after generic entry. We use appro-
priate estimation method for panel data. RESULTS: We
ﬁnd that: 1) generic entry is positively related to pre-entry
market size of the brand, but negatively inﬂuenced by the
number and the market share of the generic incumbents,
and the presence of entry-restricting conditions; 2) 
generics’ share is inﬂuenced positively by the number of
generics and HMO coverage rate, but negatively by the
generic-to-brand price ratio and the presence of entry-
restricting conditions; 3) the generic-to-brand price ratio
is larger in cases where entry-restricting conditions exist,
but smaller where there are more generic competitors or
where generics’ share is larger. Additionally, the generic-
to-brand price ratio is lower for blockbuster drugs; and
4) on average, brand prices respond to generic entry—the
inﬂation-adjusted rate of brand price change is found 
to be signiﬁcantly lower after generic entry. Finally, we
demonstrate the accuracy of our estimation model by pre-
dicting the out-of-sample experience of the drug Prozac
(ﬂuoxetine). CONCLUSIONS: Generic share inﬂuences
and is inﬂuenced by price, while the number of generic
entrants is a key determinant of generic share and generic-
to-brand price ratio. Generic competition is found to be
particularly intense for blockbuster drugs, which experi-
ence signiﬁcantly more generic entrants, price erosion and
generic penetration than other drugs.
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Historical drug sales data are frequently used for formu-
lary budget impact analyses of new pharmaceuticals.
Growth projections are either empirical or based on
simple linear regression calculations. Recent evidence
indicates that the aggregate life cycle of pharmaceuticals
approximates an “inverted U” distribution, however
information about life cycle by therapeutic category is 
not available. OBJECTIVES: Determine functional data
form to guide statistical modeling of the sales life cycle 
of pharmaceutical products, by therapeutic category.
METHODS: Pharmaceutical sales data for 1992 to 2001
were obtained from IMS Canada and classiﬁed as to type
(prescription, over the counter, diagnostic); formulation
(tablets/capsules, injectable); release mechanism (regu-
lar, extended/sustained); compounding (single, multiple
active drugs); research origin (branded, generic) and ther-
apeutic category. Records meeting the following criteria
were included in the initial analysis: prescription,
branded, tablets/capsules, and single compounds. Using
the date of ﬁrst sale, the number of months on the market
was calculated for each compound by calendar year. 
Sales data were adjusted for inﬂation using the Canadian
consumer price index (1992 = 1.00) and expressed per
1000 population (2001 Canadian census). Detailed IMS
therapeutic categories were consolidated into 59 cate-
gories. Linear regression and graphical examination
focused on the ten top selling categories. RESULTS:
For all drugs, linear regression explained only 3% of the
variance in yearly sales and showed no signiﬁcant dif-
ference by release mechanism. Graphical examination
revealed two consistent trends: 1) A sharp rise in sales
peaking at approximately 100 months followed by a slow
decay and 2) three patterns of sales: a) 2–5 “super
sellers”; b) 6–10 “above average sellers”; and c) the
majority being average sellers. CONCLUSIONS: Drug
sales are non-linear over time and are characterized by
three distinct patterns. Future models will utilize non-
linear techniques and incorporate number of branded
compounds, number and timing of generic compounds
and market share.
